{"id":"NCT00814307","sponsor":"Pfizer","briefTitle":"A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis","officialTitle":"Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 Monotherapy In Patients With Active Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-02","primaryCompletion":"2010-06","completion":"2010-06","firstPosted":"2008-12-24","resultsPosted":"2013-01-11","lastUpdate":"2013-01-18"},"enrollment":611,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Rheumatoid"],"interventions":[{"type":"DRUG","name":"CP-690,550","otherNames":[]},{"type":"DRUG","name":"CP-690,550","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Active 5mg","type":"EXPERIMENTAL"},{"label":"Active 10 mg","type":"EXPERIMENTAL"},{"label":"Placebo Sequence 1","type":"PLACEBO_COMPARATOR"},{"label":"Placebo Sequence 2","type":"PLACEBO_COMPARATOR"}],"summary":"This Phase 3 study is intended to provide evidence of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day as monotherapy in adult patients with moderate to severe Rheumatoid Arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in the Phase 2 Rheumatoid Arthritis studies.","primaryOutcome":{"measure":"Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 3","timeFrame":"Month 3","effectByArm":[{"arm":"CP-690,550 5 mg","deltaMin":59.75,"sd":null},{"arm":"CP-690,550 10 mg","deltaMin":65.7,"sd":null},{"arm":"Placebo","deltaMin":26.67,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":95,"countries":["United States","Brazil","Bulgaria","Chile","Colombia","Czechia","Dominican Republic","Germany","India","Malaysia","Mexico","Philippines","Poland","Puerto Rico","Russia","Ukraine"]},"refs":{"pmids":["39192350","38958913","38883150","37925660","37453736","36931693","36814062","36601090","36600185","36526796","35577477","34921355","34870800","33127856","32816215","30177460","29794874","28143815","26530039","26275429","25047021","22873530"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921045&StudyName=A%20Phase%203%20study%20comparing%202%20doses%20of%20CP-690%2C550%20vs.%20placebo%20for%20treatment%20of%20rheumatoid%20arthritis"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":243},"commonTop":["Upper respiratory tract infection","Headache","Urinary tract infection","Diarrhoea","Oedema peripheral"]}}